F-1: Akanda Corp. Eyes Public Offering to Fuel Expansion in Medical Cannabis Market

Akanda Corp. files for a public offering of common shares and warrants to fund capital expenditures, operations, and potential acquisitions in the burgeoning medical cannabis sector.

Summary

• Akanda Corp., a cannabis cultivation, manufacturing, and distribution company, has filed a Form F-1 registration statement for a proposed public offering.
• The offering includes common shares, warrants to purchase common shares, and pre-funded warrants to purchase common shares.
• The company intends to use the net proceeds for capital expenditures, operating capacity, working capital, general corporate purposes, refinancing existing debt, and potential acquisitions.
• Akanda Corp. is targeting the international medical cannabis market, estimated to reach $47 billion by 2027.
• The company operates through subsidiaries including Canmart Ltd. in the UK and RPK Biopharma in Portugal.
• A non-binding letter of intent to sell RPK Biopharma to Somai Pharmaceuticals Ltd. is in place, with a purchase price of $2,000,000 including certain liabilities.
• The company acquired the right to develop a Canadian farming property in British Columbia for THC and CBD facilities.
• Akanda Corp. faces risks including a limited operating history, evolving regulations, and intense competition.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights growth opportunities in the medical cannabis market and the company's strategic initiatives, it also acknowledges significant risks and financial challenges, including a limited operating history and potential going concern issues. The potential capital raise is a positive, but the need for it also underscores the company's current financial constraints.

Positives

• Canmart has a first-mover advantage in the UK medical cannabis market.
• RPK's genetics produce high THC test results, making them attractive in EU GMP markets.
• The company has an experienced management team.
• RPK's Sintra facility is a commercial-scale premium indoor EU GMP certified and licensed grow in Portugal.
• RPK has a genetics and retail partnership with Cookies.

Negatives

• The company has a limited operating history and minimal revenues to date.
• The company's financial situation raises doubt about its ability to continue as a going concern.
• Bophelo is currently in insolvency proceedings.
• The company may become involved in litigation matters that are expensive and time consuming.
• The company is subject to significant competition by new and existing competitors in the cannabis industry.

Risks

• The company's limited operating history and minimal revenues pose a risk to its financial stability.
• Evolving cannabis laws and regulations could require the company to incur substantial compliance costs.
• Increased competition in the cannabis industry may cause difficulties in generating revenues and market share.
• The company is subject to the risks inherent in an agricultural business, such as adverse weather conditions and plant diseases.
• The company is dependent on third-party suppliers, service providers, and distributors.
• The company may be unable to effectively manage future growth.
• The company is subject to the risks inherent in an agricultural business.
• The company is dependent upon its management and key employees, and the loss of any member of our management team or any key employee could have a material adverse effect on our operations.

Future Outlook

The company anticipates undertaking activities in the next 12 to 36 months to further grow Canmart, RPK, and the BC Farms business, including expanding distribution networks, pursuing accretive acquisitions, and monitoring US scheduling.

Industry Context

The announcement comes amid growing interest and investment in the international medical cannabis market, with increasing legalization and research activities driving demand.

Comparison to Industry Standards

• The document mentions competitors such as Tilray Portugal, Unipessoal, Lda, Portocanna SA, Agrivab Medical Cannabis, and Clever Leaves Portugal Unipessoal Lda in Portugal.
• It also mentions The Lyphe Group, Grow Pharma and IPS Pharma as competitors in the UK.
• The document states that RPK's EU-GMP certified product which does not require radiation gives it a competitive advantage over all of its competitors in Germany.

Legal Proceedings

• The company is involved in legal proceedings with former officers, including Tejinder Virk, Louisa Mojela, and Trevor Scott.

Related Party Transactions

• The company has incurred aggregated outstanding loans, including accrued interest, of approximately $1,429,092 from Halo (the Halo Debt), making Halo a significant creditor of the Company.
• The company has loans outstanding to 1248787 B.C. Ltd., a company controlled by Jatinder Dhaliwal, a director of the Akanda.

Stakeholder Impact

• Shareholders face potential dilution from the public offering and the exercise of warrants.
• The company's ability to execute its business plan and achieve profitability will impact shareholder value.
• Employees may be affected by potential restructuring or changes in operations.
• Customers may benefit from expanded product offerings and improved distribution channels.

Next Steps

• Negotiate and finalize the Definitive Agreement for the sale of RPK Biopharma.
• Secure necessary regulatory approvals for the sale of RPK Biopharma.
• Develop THC and CBD facilities at the acquired Canadian farming property.
• Expand the distribution network in the UK.
• Obtain licenses for THC cultivation, CBD cultivation, and hemp cultivation at the BC farm.

Key Dates

Keywords

cannabis, medical cannabis, RPK Biopharma, Canmart, public offering, EU GMP, cultivation, distribution, warrants, pre-funded warrants, Somai Pharmaceuticals, Holigen, Bophelo, AKAN, Portugal, United Kingdom, Canada